Search Results - "Hiddo L. Heerspink"

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease by Heerspink, Hiddo J. L., Perco, Paul, Mulder, Skander, Leierer, Johannes, Hansen, Michael K., Heinzel, Andreas, Mayer, Gert

“…Aims/hypothesis The sodium–glucose cotransporter 2 (SGLT2) inhibitor canagliflozin slows progression of kidney function decline in type 2 diabetes. The aim of…”
Get full text

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers by Dekkers, Claire C. J., Petrykiv, Sergei, Laverman, Gozewijn D., Cherney, David Z., Gansevoort, Ron T., Heerspink, Hiddo J. L.

“…The mechanisms by which SGLT‐2 inhibitors lower albuminuria are incompletely understood. We assessed in a post‐hoc analysis of a cross‐over trial the effects…”
Get full text

The New Biology of Diabetic Kidney Disease—Mechanisms and Therapeutic Implications by Lytvyn, Yuliya, Bjornstad, Petter, van Raalte, Daniel H, Heerspink, Hiddo L, Cherney, David Z I

“…Abstract Diabetic kidney disease remains the most common cause of end-stage kidney disease in the world. Despite reductions in incidence rates of myocardial…”
Get full text

Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program by Neuen, Brendon L, Ohkuma, Toshiaki, Neal, Bruce, Matthews, David R, de Zeeuw, Dick, Mahaffey, Kenneth W, Fulcher, Greg, Li, Qiang, Jardine, Meg, Oh, Richard, Heerspink, Hiddo L, Perkovic, Vlado

“…If SGLT2 inhibitors protect the kidneys by reducing albuminuria as hypothesized, people with type 2 diabetes mellitus (T2DM) with higher albuminuria should…”
Get full text

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial by Sen, Taha, Li, Jingwei, Neuen, Brendon L., Neal, Bruce, Arnott, Clare, Parikh, Chirag R., Coca, Steven G., Perkovic, Vlado, Mahaffey, Kenneth W., Yavin, Yshai, Rosenthal, Norman, Hansen, Michael K., Heerspink, Hiddo J. L.

“…Aims/hypothesis Higher plasma concentrations of tumour necrosis factor receptor (TNFR)-1, TNFR-2 and kidney injury molecule-1 (KIM-1) have been found to be…”
Get full text

The albuminuria‐lowering response to dapagliflozin is variable and reproducible among individual patients by Petrykiv, Sergei I., Laverman, Gozewijn D., de Zeeuw, Dick, Heerspink, Hiddo J. L.

“…Aims Albuminuria reduction is essential for renal and cardiovascular protection. We characterized the efficacy of dapagliflozin, a sodium‐glucose…”
Get full text

Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease by Pena, Michelle J., Mischak, Harald, Heerspink, Hiddo J. L.

“…The past decade has resulted in multiple new findings of potential proteomic biomarkers of diabetic kidney disease (DKD). Many of these biomarkers reflect an…”
Get full text

Protocol for a randomized study assessing the feasibility of home-based albuminuria screening among the general population: The THOMAS study by van Mil, Dominique, Kieneker, Lyanne M, Evers-Roeten, Birgitte, Thelen, Marc H M, de Vries, Hanne, Hemmelder, Marc H, Dorgelo, Annemiek, van Etten, Ronald W, Heerspink, Hiddo J L, Gansevoort, Ron T

“…Chronic kidney disease (CKD) is a rising public health problem that may progress to kidney failure, requiring kidney replacement therapy. It is also associated…”
Get full text

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era by Heerspink, Hiddo J. L., List, James, Perkovic, Vlado

“…Despite advances in pharmacotherapy, diabetic kidney disease (DKD) remains associated with a high burden of micro‐ and macrovascular complications often…”
Get full text

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors by Dekkers, Claire C. J., Gansevoort, Ron T., Heerspink, Hiddo J. L.

“…Purpose of Review Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising drug class for the treatment of diabetic kidney disease…”
Get full text

Triglyceride-rich lipoprotein and LDL particle subfractions and their association with incident type 2 diabetes: the PREVEND study by Sokooti, Sara, Flores-Guerrero, Jose L, Heerspink, Hiddo J L, Connelly, Margery A, Bakker, Stephan J L, Dullaart, Robin P F

“…Triglyceride-rich lipoproteins particles (TRLP) and low density lipoprotein particles (LDLP) vary in size. Their association with β-cell function is not well…”
Get full text

Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology by Waijer, Simke W., Provenzano, Michele, Mulder, Skander, Rossing, Peter, Persson, Frederik, Perkovic, Vlado, Heerspink, Hiddo J. L.

“…Aim To test whether a screening approach with more flexible urinary albumin creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) thresholds…”
Get full text

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure by Tye, Sok Cin, Jongs, Niels, Coca, Steven G., Sundström, Johan, Arnott, Clare, Neal, Bruce, Perkovic, Vlado, Mahaffey, Kenneth W., Vart, Priya, Heerspink, Hiddo. J. L.

“…Abstract Background Sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of kidney and heart failure events independent of glycemic effects. We…”
Get full text

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial by Clegg, Lindsay E, Penland, Robert C, Bachina, Srinivas, Boulton, David W, Thuresson, Marcus, Heerspink, Hiddo J L, Gustavson, Stephanie, Sjöström, C David, Ruggles, James A, Hernandez, Adrian F, Buse, John B, Mentz, Robert J, Holman, Rury R

“…Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes in…”
Get full text

Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years by Lawson, Claire A, Seidu, Samuel, Zaccardi, Francesco, McCann, Gerry, Kadam, Umesh T, Davies, Melanie J, Lam, Carolyn SP, Heerspink, Hiddo L., Khunti, Kamlesh

“…Heart failure (HF) together with type 2 diabetes (T2D) and chronic kidney disease (CKD) are major pandemics of the twenty first century. It is not known in…”
Get full text

A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) – Study Design and Baseline Characteristics by Eder, Susanne, Leierer, Johannes, Kerschbaum, Julia, Rosivall, Laszlo, Wiecek, Andrzej, de Zeeuw, Dick, Mark, Patrick B., Heinze, Georg, Rossing, Peter, Heerspink, Hiddo L., Mayer, Gert

“…Background/Aims: The prevalence of diabetes mellitus type 2 and kidney disease in these patients varies widely between European countries. Methods: In addition…”
Get full text

Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate by Grams, Morgan E, Sang, Yingying, Ballew, Shoshana H, Carrero, Juan Jesus, Djurdjev, Ognjenka, Heerspink, Hiddo J L, Ho, Kevin, Ito, Sadayoshi, Marks, Angharad, Naimark, David, Nash, Danielle M, Navaneethan, Sankar D, Sarnak, Mark, Stengel, Benedicte, Visseren, Frank L J, Wang, Angela Yee-Moon, Köttgen, Anna, Levey, Andrew S, Woodward, Mark, Eckardt, Kai-Uwe, Hemmelgarn, Brenda, Coresh, Josef

“…Patients with chronic kidney disease and severely decreased glomerular filtration rate (GFR) are at high risk for kidney failure, cardiovascular disease (CVD)…”
Get more information

Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial by van der Aart‐van der Beek, Annemarie B., Clegg, Lindsay E., Penland, Robert C., Boulton, David W., Sjöström, C. David, Mentz, Robert J., Holman, Rury R., Heerspink, Hiddo J. L.

“…The effects of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) on renal outcomes in patients with type 2 diabetes at high cardiovascular risk are modest…”
Get full text

Obesity-Related Kidney Disease: Current Understanding and Future Perspectives by Kreiner, Frederik F, Schytz, Philip Andreas, Heerspink, Hiddo J L, von Scholten, Bernt Johan, Idorn, Thomas

“…Obesity is a serious chronic disease and an independent risk factor for the new onset and progression of chronic kidney disease (CKD). CKD prevalence is…”
Get full text

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis by Rossing, Peter, Bain, Stephen C., Bosch-Traberg, Heidrun, Sokareva, Ekaterina, Heerspink, Hiddo J. L., Rasmussen, Søren, Mellbin, Linda G.

“…Abstract Background Semaglutide is a glucose-lowering treatment for type 2 diabetes (T2D) with demonstrated cardiovascular benefits; semaglutide may also have…”
Get full text